About gene therapy

The goal of gene therapy is to treat diseases caused by single defective genes or to increase the expression of existing genes

Gene therapy technology is unique in that it makes it possible to replace defective or missing genes or, in the case of CombiGene’s method in the CG01 project, to increase the expression of existing genes.

Currently, some 2,800 such diseases that are caused by single defective genes are known and, for the majority of them, there are no adequate treatment methods. Gene therapy is one of the most exciting areas of development in the pharma industry, thanks to the unique possibilities for precisely targeted therapy and the potential for meeting very great medical needs.
Unlike conventional drug treatment of chronic diseases, which requires continuous medication, gene therapy has the great advantage of being able to achieve a long-term effect after just one or a few treatments. Significant advances in gene therapy have been made in the past 5-10 years and there is considerable interest in this technology among the major pharmaceutical companies, as evidenced by, among other things, the large number of acquisitions during recent years. Considering the many advantages of gene therapy, and the many research and development projects now under way throughout the world, it is reasonable to assume that the number of approved gene therapy products will continue to grow dramatically over the coming years. A large number of patients whose diseases cannot be adequately treated can thereby enjoy significantly better lives, thanks to the new therapies.

CombiGene’s candidate drug increases expression of NPY and its receptor Y2, suppresses glutamate release (the cause of epileptic seizures) and thereby reduces the number of epileptic seizures.

About gene therapy

The goal of gene therapy is to treat diseases caused by single defective genes or to increase the expression of existing genes

Gene therapy technology is unique in that it makes it possible to replace defective or missing genes or, in the case of CombiGene’s method in the CG01 project, to increase the expression of existing genes.

Currently, some 2,800 such diseases that are caused by single defective genes are known and, for the majority of them, there are no adequate treatment methods. Gene therapy is one of the most exciting areas of development in the pharma industry, thanks to the unique possibilities for precisely targeted therapy and the potential for meeting very great medical needs.
Unlike conventional drug treatment of chronic diseases, which requires continuous medication, gene therapy has the great advantage of being able to achieve a long-term effect after just one or a few treatments. Significant advances in gene therapy have been made in the past 5-10 years and there is considerable interest in this technology among the major pharmaceutical companies, as evidenced by, among other things, the large number of acquisitions during recent years. Considering the many advantages of gene therapy, and the many research and development projects now under way throughout the world, it is reasonable to assume that the number of approved gene therapy products will continue to grow dramatically over the coming years. A large number of patients whose diseases cannot be adequately treated can thereby enjoy significantly better lives, thanks to the new therapies.

CombiGene’s candidate drug increases expression of NPY and its receptor Y2, suppresses glutamate release (the cause of epileptic seizures) and thereby reduces the number of epileptic seizures.

About gene therapy

The goal of gene therapy is to treat diseases caused by single defective genes or to increase the expression of existing genes

Gene therapy technology is unique in that it makes it possible to replace defective or missing genes or, in the case of CombiGene’s method in the CG01 project, to increase the expression of existing genes.

Currently, some 2,800 such diseases that are caused by single defective genes are known and, for the majority of them, there are no adequate treatment methods. Gene therapy is one of the most exciting areas of development in the pharma industry, thanks to the unique possibilities for precisely targeted therapy and the potential for meeting very great medical needs.
Unlike conventional drug treatment of chronic diseases, which requires continuous medication, gene therapy has the great advantage of being able to achieve a long-term effect after just one or a few treatments. Significant advances in gene therapy have been made in the past 5-10 years and there is considerable interest in this technology among the major pharmaceutical companies, as evidenced by, among other things, the large number of acquisitions during recent years. Considering the many advantages of gene therapy, and the many research and development projects now under way throughout the world, it is reasonable to assume that the number of approved gene therapy products will continue to grow dramatically over the coming years. A large number of patients whose diseases cannot be adequately treated can thereby enjoy significantly better lives, thanks to the new therapies.

CombiGene’s candidate drug increases expression of NPY and its receptor Y2, suppresses glutamate release (the cause of epileptic seizures) and thereby reduces the number of epileptic seizures.

CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

Linked In     Twitter      Facebook